AbbVie (NYSE: ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

AbbVie's HUMIRA® (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision[1]May 27, 2016 7:00 AM Stocks with Implied Volatility MovementMay 27, 2016 6:09 AM AbbVie to Present at the Jefferies 2016 Healthcare ConferenceMay 26, 2016 8:00 AM